Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”)
today announced the appointment of Connie A. Stefankiewicz and
Loreto Grimaldi to its Board of Directors (the “Board”) following
Emblem’s annual and special shareholders’ meeting. Harvey Shapiro,
current chair, and Maxim Zavet have stepped down from the Board,
and the Board would like to thank them for their immense
contributions since Emblem’s inception. Ms. Stefankiewicz and Mr.
Grimaldi will join current Board members Daniel Milliard, Jeffrey
Fineberg, John H. Stewart, Terry Johnson and Nick Dean. In
connection with the resignation of Mr. Shapiro, the Board has
appointed independent director Mr. Milliard as the new chair of the
Board.
“Both Connie and Loreto bring an incredible amount of experience
to our Board. Connie possesses an impressive background with a
leading Canadian financial institution, most recently serving as
Chief Marketing Officer. This expertise will be a valuable asset
for Emblem as we pursue our strategic focus on innovation and brand
building,” said Nick Dean, CEO of Emblem. “Loreto also brings a
strong background as a business partner and trusted advisor to
C-suite leaders and boards of directors. As an accomplished senior
executive with global legal and business transformation experience,
he brings a wealth of knowledge to help inform and shape Emblem’s
global growth strategy.”
“With a strategic focus on product innovation, brand building
and strengthening its distribution channels, Emblem is at a
critical juncture in its evolution,” said Dean. “The Company is
poised to see a number of initiatives come to fruition over the
coming months, including the opening of a 30,000 sq. ft. Product
Innovation Centre with GMP capabilities, entry into the German
market in mid-2019, and the continued growth of the both medical
and adult-use cannabis markets domestically. The bench strength of
the Board will provide the guidance and expertise to see Emblem
through this exciting period of growth and transformation.”
In connection, subject to receipt of the TSX Venture Exchange’s
approval of both Ms. Stefankiewicz and Mr. Grimaldi’s appointment,
the Company has approved the granting of 250,000 incentive stock
options (the “Options”) to each of Ms. Stefankiewicz and Mr.
Grimaldi. Such Options are exercisable at a price of $1.37 per
share for a period of five years from the date of grant and shall
vest over a period of three years in equal annual installments of
one-third of the Options on each of November 6, 2019, 2020 and
2021.
In addition, the Board has also approved the granting of
1,100,000 Options to certain employees of the Company. Such Options
are exercisable at a price of $1.37 per share for a period of five
years and are subject to vesting as to one-third the number of
Options granted on each of November 6, 2019, 2020 and 2021.
All other items were passed at the meeting. Full details of all
policies and proposals are more fully described in the Company's
Management Information Circular as filed on www.sedar.com.
About EmblemEmblem is a fully integrated
cannabis company focused on driving shareholder value through
product innovation, brand relevance, and access to patient and
consumer channels. Through its wholly-owned subsidiary Emblem
Cannabis Corporation, Emblem is licensed to cultivate, process, and
sell cannabis and cannabis derivatives in Canada under the Cannabis
Act. Emblem’s state-of-the-art indoor cannabis cultivation facility
and Product Innovation Centre is located in Paris, Ontario. Emblem
is also the parent company of GrowWise Health Limited, one of
Canada’s leading cannabis education services. Emblem trades under
the ticker symbol EMC on the TSX Venture Exchange.
For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
Morgan CatesH+K
Strategies416.413.4649Morgan.cates@hkstrategies.ca
For investor inquiries, please contact:
Ethan KarayannopoulosInvestor RelationsEmblem
Corp.647.748.9696ethank@emblemcorp.com
Alex StojanovicChief Financial OfficerEmblem
Corp.416.923.1331alexs@emblemcorp.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements
and forward-looking information (collectively referred to herein as
“forward-looking statements”) within the meaning of applicable
Canadian securities laws. All statements other than statements of
present or historical fact are forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as “anticipate”, “achieve”, “could”,
“believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”,
“estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should”
or similar words, including negatives thereof, suggesting future
outcomes. Management of the Company believes the expectations
reflected in such forward-looking statements are reasonable as of
the date hereof but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon. Various material
factors and assumptions are typically applied in drawing
conclusions or making the forecasts or projections set out in
forward-looking statements. Those material factors and assumptions
are based on information currently available to the Company,
including data from publicly available governmental sources as well
as from market research and industry analysis and on assumptions
based on data and knowledge of this industry which Emblem believes
to be reasonable. However, although generally indicative of
relative market positions, market shares and performance
characteristics, such data is inherently imprecise. While Emblem is
not aware of any misstatement regarding any industry or government
data presented herein, the medical marijuana industry involves
risks and uncertainties and is subject to change based on various
factors.
Forward-looking statements are not a guarantee of future
performance and are subject to and involve a number of known and
unknown risks and uncertainties, many of which are beyond the
control of the Company, which may cause the Company’s actual
performance and results to differ materially from any projections
of future performance or results expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks identified in the Company’s
December 31, 2017 Management’s Discussion and Analysis, which has
been filed with the Canadian Securities Administrators and
available on www.sedar.com. Any forward-looking statements are made
as of the date hereof and, except as required by law, the Company
assumes no obligation to publicly update or revise such statements
to reflect new information, subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Emblem Corp (TSXV:EMC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emblem Corp (TSXV:EMC)
Historical Stock Chart
From Apr 2023 to Apr 2024